Literature DB >> 6547457

Coagulation factor Va binds to human umbilical vein endothelial cells and accelerates protein C activation.

I Maruyama, H H Salem, P W Majerus.   

Abstract

In vitro the rate of protein C activation by thrombin is significantly accelerated by two distinct cofactors (a) the endothelial cell surface protein, thrombomodulin, and (b) human coagulation Factor Va. We have recently reported that the activity of Factor Va is contained in the 78,000-D light chain. In this study we have investigated the effects of Factor Va and its light chain on the activation of protein C in the presence of cultured endothelial cells. Thrombin-catalyzed protein C activation on human umbilical vein endothelial cells was enhanced by Factor Va. The ability of Factor Va to stimulate protein C activation on these cells was saturated at 50 nM Factor Va and was observed at several protein C concentrations. Isolated Factor Va light chain in concentrations up to 50 nM also accelerated protein C activation on endothelial cells, but higher concentrations inhibited the reaction. The effects of Factor Va or its light chain on protein C activation were also shown on a mouse hemangioma cell line but not on human fibroblasts nor on a human amelanotic melanoma cell line. Protein C activation on endothelial cells was partially inhibited by a goat anti-thrombomodulin antibody and further addition of a polyclonal rabbit anti-Factor V(Va) antibody resulted in additional inhibition. Endothelial cells grown in medium supplemented with human serum, devoid of Factor V coagulant activity, contained cell surface Factor V(Va) (approximately 15,000 molecules/cell) as measured by the binding of a monoclonal IgG directed against Factor V(Va). These cells also bound an additional 6,000-10,000 molecules Factor Va per cell as determined by direct binding studies using 125I-Factor Va. We suggest that thrombomodulin and Factor Va act in concert to regulate protein C activation on the surface of endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6547457      PMCID: PMC425204          DOI: 10.1172/JCI111405

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  A new vitamin K-dependent protein. Purification from bovine plasma and preliminary characterization.

Authors:  J Stenflo
Journal:  J Biol Chem       Date:  1976-01-25       Impact factor: 5.157

2.  Protein A from Staphylococcus aureus. Its isolation by affinity chromatography and its use as an immunosorbent for isolation of immunoglobulins.

Authors:  H Hjelm; K Hjelm; J Sjöquist
Journal:  FEBS Lett       Date:  1972-11-15       Impact factor: 4.124

3.  The inhibition of blood coagulation by activated Protein C through the selective inactivation of activated Factor V.

Authors:  F J Walker; P W Sexton; C T Esmon
Journal:  Biochim Biophys Acta       Date:  1979-12-07

4.  Platelet adherence to cultured vascular cells: influence of prostacyclin (PGI2).

Authors:  G L Fry; R L Czervionke; J C Hoak; J B Smith; D L Haycraft
Journal:  Blood       Date:  1980-02       Impact factor: 22.113

5.  Evidence for the formation of an ester between thrombin and heparin cofactor.

Authors:  W G Owen
Journal:  Biochim Biophys Acta       Date:  1975-10-20

6.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria.

Authors:  E A Jaffe; R L Nachman; C G Becker; C R Minick
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

7.  Hemorrhagic death associated with a high titer factor V inhibitor.

Authors:  M C Coots; A F Muhleman; H I Glueck
Journal:  Am J Hematol       Date:  1978       Impact factor: 10.047

8.  Proteolytic activation of protein C from bovine plasma.

Authors:  W Kisiel; L H Ericsson; E W Davie
Journal:  Biochemistry       Date:  1976-11-02       Impact factor: 3.162

9.  Preparation and properties of bovine factor VIII (antihemophilic factor).

Authors:  G A Vehar; E W Davie
Journal:  Biochemistry       Date:  1980-02-05       Impact factor: 3.162

10.  Patients with congenital factor V deficiency have decreased factor Xa binding sites on their platelets.

Authors:  J P Miletich; D W Majerus; P W Majerus
Journal:  J Clin Invest       Date:  1978-10       Impact factor: 14.808

View more
  11 in total

1.  Cloning of a cDNA coding for human factor V, a blood coagulation factor homologous to factor VIII and ceruloplasmin.

Authors:  W H Kane; E W Davie
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

2.  The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism.

Authors:  Kazuhiro Abeyama; David M Stern; Yuji Ito; Ko-ichi Kawahara; Yasushi Yoshimoto; Motoyuki Tanaka; Tomonori Uchimura; Nobuo Ida; Yoshiaki Yamazaki; Shingo Yamada; Yasuhiko Yamamoto; Hiroshi Yamamoto; Satoshi Iino; Noboru Taniguchi; Ikuro Maruyama
Journal:  J Clin Invest       Date:  2005-04-14       Impact factor: 14.808

3.  The effect of phospholipids on the activation of protein C by the human thrombin-thrombomodulin complex.

Authors:  J M Freyssinet; J Gauchy; J P Cazenave
Journal:  Biochem J       Date:  1986-08-15       Impact factor: 3.857

4.  Human thrombomodulin is not an efficient inhibitor of the procoagulant activity of thrombin.

Authors:  I Maruyama; H H Salem; H Ishii; P W Majerus
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

5.  Active site-labeled prothrombin inhibits prothrombinase in vitro and thrombosis in vivo.

Authors:  Heather K Kroh; Peter Panizzi; Svetlana Tchaikovski; T Regan Baird; Nancy Wei; Sriram Krishnaswamy; Guido Tans; Jan Rosing; Bruce Furie; Barbara C Furie; Paul E Bock
Journal:  J Biol Chem       Date:  2011-04-29       Impact factor: 5.157

6.  Enhanced thrombin generation and platelet binding on herpes simplex virus-infected endothelium.

Authors:  M R Visser; P B Tracy; G M Vercellotti; J L Goodman; J G White; H S Jacob
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

7.  Activation of prothrombin in the presence of human umbilical-vein endothelial cells.

Authors:  P Schoen; C Reutelingsperger; T Lindhout
Journal:  Biochem J       Date:  1992-02-01       Impact factor: 3.857

8.  Recombinant human soluble thrombomodulin is active against hemophagocytic lymphohistiocytosis associated with acquired immunodeficiency syndrome.

Authors:  SungGi Chi; Takayuki Ikezoe; Asako Takeuchi; Masato Takaoka; Akihito Yokoyama
Journal:  Int J Hematol       Date:  2013-10-08       Impact factor: 2.490

9.  A donor thrombomodulin gene variation predicts graft-versus-host disease development and mortality after bone marrow transplantation.

Authors:  Haruka Nomoto; Akiyoshi Takami; J Luis Espinoza; Keitaro Matsuo; Shohei Mizuno; Makoto Onizuka; Koichi Kashiwase; Yasuo Morishima; Takahiro Fukuda; Yoshihisa Kodera; Noriko Doki; Koichi Miyamura; Takehiko Mori; Shinji Nakao; Shigeki Ohtake; Eriko Morishita
Journal:  Int J Hematol       Date:  2015-08-06       Impact factor: 2.490

10.  Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta.

Authors:  I Maruyama; C E Bell; P W Majerus
Journal:  J Cell Biol       Date:  1985-08       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.